Delve into the increasingly dynamic landscape of ALS treatment development with thirteen companies advancing candidates in ...
Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease that remains incurable, despite decades of basic and clinical research. Key stakeholders—including the US National ...
Hosted on MSN3d
FDA lifts clinical hold on Amylyx’s Phase I ALS trialThis is the latest venture for Amylyx into the ALS field after its previous therapy Relyvrio was pulled from the market in ...
After raising questions surrounding dosing levels, the FDA has freed Amylyx’s early-stage amyotrophic lateral sclerosis (ALS) ...
company is now working on screening, enrollment and dosing for a Phase 1 trial of AMX0114, a drug for people living with ALS--amyotrophic lateral sclerosis--a fatal disease that triggers ...
Zydus Lifesciences announced that Usnoflast, a treatment for amyotrophic lateral sclerosis (ALS), has received Orphan Drug Designation from the US FDA. This designation supports the development of ...
Eli Lilly partnership aims to identify new treatments for ALS based on antibodies from people with very slow disease ...
Zydus has announced that the USFDA has granted Orphan Drug Designation (ODD) to Usnoflast, a novel oral NLRP3 inhibitor, for ...
Artificial-intelligence software is being used to re-create Moshe Nussbaum's widely recognized, distinctive voice ...
Zydus’ Usnoflast receives US FDA orphan drug designation to treat amyotrophic lateral sclerosis: Our Bureau, Mumbai Thursday, January 23, 2025, 12:15 Hrs [IST] Zydus, a leading, ...
Today on Louisiana Considered, an ALS patient and advocate tells us about the crucial role caregivers play in supporting ...
A New Bedford man was sentenced to prison for conspiring to steal and then depositing over $450,000 from a U.S. Marine ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback